NLRP3 and gout: While clinical evaluation of MCC950 led to its discontinuation due to hepatotoxicity (Chen et al., 2021), these early efforts provided the scientific premise for other small-molecule NLRP3 inhibitors that are in various phases of clinical trials, including dapansutrile, a specific NLRP3 inhibitor (Marchetti et al., 2018; Sanchez-Fernandez et al., 2019) that has been shown to be safe in heart failure (Wohlford et al., 2020) and gout (Kluck et al., 2020).